New Publication on CMC-001

Posted August 11, 2010 by CMC Contrast

In the recent edition of Investigative Radiology Dr. Matthias Reif and colleagues at the Charité – Universitätsmedizin in Berlin, Germany have published an article from a phase II with CMC-001 entitled; “Manganese-Based Oral Contrast Agent for Liver Magnetic Resonance Imaging - Evaluation of the Time Course and Dose Response of Liver Signal Intensity Enhancement” (Rief M et al .Invest Radiol 2010; 45).

Based on the results from the study Dr. Reif and colleagues concluded:
“In conclusion, our study demonstrates that CMC-001 administered as single dose is a safe and effective oral contrast agent in patients who undergo MRI for evaluation of liver metastases. Considering the time course of liver SI enhancement and LLC, our results suggest that the diagnostic time window for liver MR imaging is between 2 hours and 6 hours after oral administration of CMC-001. From a logistic standpoint, CMC-001 could simplify liver-specific MR imaging and reduce imaging time and costs in carefully selected patients.”

Access to the article can be obtained through the following link:
http://journals.lww.com/investigativeradiology/Abstract/publishahead/Manganese_Based_Oral_Contrast_Agent_for_Liver.99828.aspx

For further information on CMC-001 please contact:
Director of Business Development Thomas Grönberg - E-mail: or Director of Medical Affairs Jan Trøst Jørgensen – E-mail: